Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.64 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.64 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.64 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.64 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | PRNP | P04156 | 1/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.64 |
| ▸ | NQO2 | P16083 | 1/20 | 0.64 |
| ▸ | MTOR | P42345 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290032 | 1.00 | NR4A2 (0.67) | NR4A2CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL4285928 | 1.00 | NR4A2 (0.67) | NR4A2CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL15476136 | 0.93 | NR4A2 (0.68) | NR4A2CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL4281551 | 0.87 | KCNH2 (0.75) | NR4A2CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL4284573 | 0.87 | KCNH2 (0.75) | NR4A2CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL4281066 | 0.87 | KCNH2 (0.75) | NR4A2CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL30817262 | 0.87 | NR4A2 (0.71) | NR4A2CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL20768111 | 0.85 | NR4A2 (0.79) | NR4A2CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL29421608 | 0.85 | NR4A2 (0.79) | NR4A2CHRM2CHRM4CHRM5ADRA2A | |
| SCHEMBL7838139 | 0.85 | NR4A2 (0.72) | NR4A2CHRM2CHRM4CHRM5ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014786-A1 | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation | RAUT RAJEEV | 2006-01-19 | — | — | US | claimed |
| EP-0656353-B1 | Aminochinoline derivates useful in the treatment of malaria | HOFFMANN LA ROCHE (CH) | 1998-06-03 | — | — | EP | claimed |
| EP-0656353-A1 | Aminochinoline derivates useful in the treatment of malaria | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-07 | — | — | EP | claimed |
| JP-7188174-A | — | — | None | — | — | JP | disclosed |
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2023-12-28 | — | — | US | disclosed |
| US-20150231237-A1 | METHODS AND PRODUCTS FOR TREATING PROLIFERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-08-20 | — | — | US | disclosed |
| US-9073985-B2 | Methods and products for treating proliferative diseases | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-07-07 | — | — | US | disclosed |
| US-20130296237-A1 | Use Of Chloroquine To Treat Metabolic Syndrome | UNIV WASHINGTON (US) | 2013-11-07 | — | — | US | disclosed |
| US-8440695-B2 | Use of chloroquine to treat metabolic syndrome | ST JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110318335-A1 | METHODS AND PRODUCTS FOR TREATING PROLIFERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2011-12-29 | — | — | US | disclosed |
| US-20090099134-A1 | TREATMENT OF DNA DAMAGE RELATED DISORDERS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2009-04-16 | — | — | US | disclosed |
| US-7084157-B2 | Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation | RAUT RAJEEV | 2006-08-01 | — | — | US | disclosed |
| US-20060014786-A1 | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation | RAUT RAJEEV | 2006-01-19 | — | — | US | disclosed |
| US-20050124653-A1 | Treatment of dna damage related disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-09 | — | — | US | disclosed |
| US-20050032834-A1 | Treatment of DNA damage related disorders | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2005-02-10 | — | — | US | disclosed |
| US-20050014785-A1 | Treatment of radiation disorders | PERLEGEN SCIENCES, INC. (US) | 2005-01-20 | — | — | US | disclosed |
| WO-2004050837-A2 | TREATMENT OF DNA DAMAGE RELATED DISORDERS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2004-06-17 | — | — | WO | disclosed |
| EP-0656353-B1 | Aminochinoline derivates useful in the treatment of malaria | HOFFMANN LA ROCHE (CH) | 1998-06-03 | — | — | EP | disclosed |
| JP-H07188174-A | AMINOQUINOLINE DERIVATIVE | F HOFFMANN LA ROCHE AG | 1995-07-25 | — | — | JP | disclosed |
| EP-0656353-A1 | Aminochinoline derivates useful in the treatment of malaria | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014785-A1 | Treatment of radiation disorders | XRCC5, XRCC6, QTRT1 | NR4A2 2599/4885CHRM2 4278/4885CHRM4 4731/4885 |
| US-20090099134-A1 | TREATMENT OF DNA DAMAGE RELATED DISORDERS | BRCA1, ERCC4, POLN | NR4A2 2195/4885CHRM2 4789/4885CHRM4 4827/4885 |
| US-20050124653-A1 | Treatment of dna damage related disorders | ERCC1, ERCC5, ERCC2 | NR4A2 3241/4885CHRM2 4693/4885CHRM4 4785/4885 |
| US-20110318335-A1 | METHODS AND PRODUCTS FOR TREATING PROLIFERATIVE DISEASES | BECN1, G6PD, KDR | NR4A2 3362/4885CHRM2 4511/4885CHRM4 4757/4885 |
| US-20060014786-A1 | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation | AQP4, IL5, CCL11 | NR4A2 435/4885CHRM2 653/4885CHRM4 369/4885 |
| US-20130296237-A1 | Use Of Chloroquine To Treat Metabolic Syndrome | NPC1L1, ECHS1, PCSK9 | NR4A2 3782/4885CHRM2 2810/4885CHRM4 3540/4885 |
| US-20050032834-A1 | Treatment of DNA damage related disorders | BRCA1, ERCC4, POLN | NR4A2 2195/4885CHRM2 4789/4885CHRM4 4827/4885 |
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | ERCC4, LIG4, LIG3 | NR4A2 2104/4885CHRM2 4834/4885CHRM4 4712/4885 |
| US-20150231237-A1 | METHODS AND PRODUCTS FOR TREATING PROLIFERATIVE DISEASES | BECN1, G6PD, VHL | NR4A2 3339/4885CHRM2 4571/4885CHRM4 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.